Infectious RNA vaccine protects mice against chikungunya virus infection

[1]  H. Feldmann,et al.  An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates , 2020, Science Translational Medicine.

[2]  Jie Zhou,et al.  Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice , 2020, Nature Communications.

[3]  N. Wressnigg,et al.  Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial. , 2020, The Lancet. Infectious diseases.

[4]  D. Weissman,et al.  mRNA vaccines — a new era in vaccinology , 2018, Nature Reviews Drug Discovery.

[5]  U. Şahin,et al.  Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  P. Pushko,et al.  Plasmid DNA launches live-attenuated Japanese encephalitis virus and elicits virus-neutralizing antibodies in BALB/c mice. , 2017, Virology.

[7]  D. Voss,et al.  A thermostable messenger RNA based vaccine against rabies , 2017, PLoS neglected tropical diseases.

[8]  P. Roques,et al.  Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus. , 2017, JCI insight.

[9]  Justin M. Richner,et al.  Modified mRNA Vaccines Protect against Zika Virus Infection , 2017, Cell.

[10]  Daniel G. Anderson,et al.  An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model , 2017, Scientific Reports.

[11]  D. Weissman,et al.  Zika virus protection by a single low dose nucleoside modified mRNA vaccination , 2017, Nature.

[12]  B. Graham,et al.  A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation , 2016, Nature Communications.

[13]  D. Voss,et al.  An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs , 2016, PLoS neglected tropical diseases.

[14]  S. Weaver,et al.  DNA-launched live-attenuated vaccines for biodefense applications , 2016, Expert review of vaccines.

[15]  V. Yamshchikov,et al.  Development of a human live attenuated West Nile infectious DNA vaccine: Suitability of attenuating mutations found in SA14-14-2 for WN vaccine design. , 2016, Virology.

[16]  T. Ahola,et al.  Differential Phosphatidylinositol-3-Kinase-Akt-mTOR Activation by Semliki Forest and Chikungunya Viruses Is Dependent on nsP3 and Connected to Replication Complex Internalization , 2015, Journal of Virology.

[17]  G. L’Ambert,et al.  Chikungunya outbreak in Montpellier, France, September to October 2014. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[18]  I. Lukashevich,et al.  Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone. , 2015, The Journal of general virology.

[19]  N. Kedersha,et al.  Viral and Cellular Proteins Containing FGDF Motifs Bind G3BP to Block Stress Granule Formation , 2015, PLoS pathogens.

[20]  K. Ljungberg,et al.  Self-replicating alphavirus RNA vaccines , 2015, Expert review of vaccines.

[21]  C. Mandl,et al.  A cationic nanoemulsion for the delivery of next-generation RNA vaccines. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  I. Lukashevich,et al.  Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice. , 2014, Virology.

[23]  L. Ng,et al.  Prime-Boost Immunization Strategies against Chikungunya Virus , 2014, Journal of Virology.

[24]  E. Wang,et al.  DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice. , 2014, The Journal of infectious diseases.

[25]  T. Ahola,et al.  The C-Terminal Repeat Domains of nsP3 from the Old World Alphaviruses Bind Directly to G3BP , 2014, Journal of Virology.

[26]  A. Nisalak,et al.  Kinetics of Chikungunya Infections during an Outbreak in Southern Thailand, 2008–2009 , 2014, The American journal of tropical medicine and hygiene.

[27]  K. Ljungberg,et al.  Intradermal electroporation of RNA. , 2014, Methods in molecular biology.

[28]  P. Roques,et al.  Novel Attenuated Chikungunya Vaccine Candidates Elicit Protective Immunity in C57BL/6 mice , 2013, Journal of Virology.

[29]  J. Drexler,et al.  Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout , 2013, Virology Journal.

[30]  E. Wang,et al.  Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine. , 2013, Vaccine.

[31]  G. B. Karlsson Hedestam,et al.  Sequestration of G3BP coupled with efficient translation inhibits stress granules in Semliki Forest virus infection , 2012, Molecular biology of the cell.

[32]  D. Vaughn,et al.  US Military contributions to the global response to pandemic chikungunya. , 2012, Vaccine.

[33]  A. P. Adams,et al.  Attenuation of Chikungunya Virus Vaccine Strain 181/Clone 25 Is Determined by Two Amino Acid Substitutions in the E2 Envelope Glycoprotein , 2012, Journal of Virology.

[34]  K. Ljungberg,et al.  Intradermal Electroporation of Naked Replicon RNA Elicits Strong Immune Responses , 2012, PloS one.

[35]  T. Ahola,et al.  Inhibitors of Alphavirus Entry and Replication Identified with a Stable Chikungunya Replicon Cell Line and Virus-Based Assays , 2011, PloS one.

[36]  E. Wang,et al.  Novel Chikungunya Vaccine Candidate with an IRES-Based Attenuation and Host Range Alteration Mechanism , 2011, PLoS pathogens.

[37]  P. Liljeström,et al.  Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines , 2011, Virology Journal.

[38]  Thibaut Larcher,et al.  Chikungunya Virus Arthritis in Adult Wild-Type Mice , 2010, Journal of Virology.

[39]  Karine Labadie,et al.  Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. , 2010, The Journal of clinical investigation.

[40]  Alain Michault,et al.  Type I IFN controls chikungunya virus via its action on nonhematopoietic cells , 2010, The Journal of experimental medicine.

[41]  A. Baum,et al.  Induction of type I interferon by RNA viruses: cellular receptors and their substrates , 2009, Amino Acids.

[42]  Hiroki Kato,et al.  Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  P. Libby,et al.  Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis. , 2008, The American journal of pathology.

[44]  X. de Lamballerie,et al.  Infectious clones of Chikungunya virus (La Réunion isolate) for vector competence studies. , 2006, Vector borne and zoonotic diseases.

[45]  A. Pichlmair,et al.  RIG-I-Mediated Antiviral Responses to Single-Stranded RNA Bearing 5'-Phosphates , 2006, Science.

[46]  Frank Kunst,et al.  Genome Microevolution of Chikungunya Viruses Causing the Indian Ocean Outbreak , 2006, PLoS medicine.

[47]  P. Liljeström,et al.  MyD88 Expression Is Required for Efficient Cross-Presentation of Viral Antigens from Infected Cells , 2005, Journal of Virology.

[48]  R. Flavell,et al.  Toll-like receptor 3 promotes cross-priming to virus-infected cells , 2005, Nature.

[49]  T. Dubensky,et al.  An Alphavirus Replicon Particle Chimera Derived from Venezuelan Equine Encephalitis and Sindbis Viruses Is a Potent Gene-Based Vaccine Delivery Vector , 2003, Journal of Virology.

[50]  M. Murphy,et al.  Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. , 2001, The Journal of infectious diseases.

[51]  T. Ahola,et al.  Elimination of Phosphorylation Sites of Semliki Forest Virus Replicase Protein nsP3* , 2001, The Journal of Biological Chemistry.

[52]  G. Rhodes,et al.  Self-replicating Semliki Forest virus RNA as recombinant vaccine. , 1994, Vaccine.

[53]  P. Liljeström,et al.  A New Generation of Animal Cell Expression Vectors Based on the Semliki Forest Virus Replicon , 1991, Bio/Technology.

[54]  P. Repik,et al.  Development of an attenuated strain of chikungunya virus for use in vaccine production. , 1986, Vaccine.

[55]  U. Linne,et al.  Microalgae as bioreactors for bioplastic production , 2011, Microbial cell factories.